» Articles » PMID: 37658212

Organ-specific Off-target Effects of Pim/ZIP Kinase Inhibitors Suggest Lack of Contractile Pim Kinase Activity in Prostate, Bladder, and Vascular Smooth Muscle

Overview
Specialty Pharmacology
Date 2023 Sep 1
PMID 37658212
Authors
Affiliations
Soon will be listed here.
Abstract

Smooth muscle contraction by Pim kinases and ZIPK has been suggested, but evidence for lower urinary tract organs or using Pim-selective inhibitor concentrations is not yet available. Here, we assessed effects of the Pim inhibitors AZD1208 and TCS PIM-1 and the dual ZIPK/Pim inhibitor HS38 on contractions of human prostate and bladder tissues and of porcine interlobar arteries. Human tissues were obtained from radical prostatectomy and radical cystectomy and renal interlobar arteries from pigs. Contractions were studied in an organ bath. Noradrenaline-, phenylephrine- and methoxamine-induced contractions were reduced (up to > 50%) with 500-nM AZD1208 in prostate tissues and to lesser degree and not consistently with all agonists in interlobar arteries. A total of 100-nM AZD1208 or 500-nM TCS PIM-1 did not affect agonist-induced contractions in prostate tissues. Decreases in agonist-induced contractions with 3-µM HS38 in prostate tissues and interlobar arteries were of small extent and did not occur with each agonist. Carbachol-induced contractions in detrusor tissues were unchanged with AZD1208 (500 nM) or HS38. Electric field stimulation-induced contractions were not affected with AZD1208 or HS38 in any tissue, but slightly reduced with 500-nM TCS PIM-1 in prostate tissues. Concentration-dependent effects of Pim inhibitors suggest lacking Pim-driven smooth muscle contraction in the prostate, bladder, and interlobar arteries but point to organ-specific functions of off-targets. Procontractile functions of ZIPK in the prostate and interlobar arteries may be limited and are lacking in the detrusor.

Citing Articles

Smooth muscle contractility of laser-enucleated prostate tissues and impacts of preoperative α-blocker treatment in patients with and without catheterization.

Keller P, Hu S, Berger L, Nicola P, Schierholz F, Tamalunas A Sci Rep. 2025; 15(1):4985.

PMID: 39929919 PMC: 11811036. DOI: 10.1038/s41598-025-88884-7.

References
1.
Cheney I, Yan S, Appleby T, Walker H, Vo T, Yao N . Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett. 2007; 17(6):1679-83. DOI: 10.1016/j.bmcl.2006.12.086. View

2.
Adler D, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S . The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?. Mol Med Rep. 2011; 5(2):313-6. DOI: 10.3892/mmr.2011.647. View

3.
Michel M, Cardozo L, Chermansky C, Cruz F, Igawa Y, Lee K . Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacol Rev. 2023; 75(4):554-674. DOI: 10.1124/pharmrev.121.000523. View

4.
Zhou B, Perel P, Mensah G, Ezzati M . Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021; 18(11):785-802. PMC: 8162166. DOI: 10.1038/s41569-021-00559-8. View

5.
Scarpa M, Kapoor S, Tvedte E, Doshi K, Zou Y, Singh P . Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. Oncotarget. 2021; 12(18):1763-1779. PMC: 8416564. DOI: 10.18632/oncotarget.28042. View